AstraZeneca PLC on Monday mentioned its most cancers drug Enhertu has proven clinically significant and sturdy responses throughout a number of HER2-expressing superior strong tumors in its DESTINY-PanTumor02 Phase II trial.
The Anglo-Swedish pharma main
AZN,
AZN,
mentioned Enhertu–trastuzumab deruxtecan, which it’s collectively creating and commercializing with Daiichi Sankyo–had met prespecified standards for goal response fee and length of response.
“Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumor settings with significant unmet need are very encouraging,” mentioned Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi.
Write to Elena Vardon at elena.vardon@wsj.com
Source web site: www.marketwatch.com
